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Abstract
Objective: Previous research suggests that reproductive hormones are potential affective modulators in mood
disorders and may influence response to antidepressant medications. To our knowledge, there are no data on
relationships between hormonal status and response to psychotherapy for recurrent major depressive disorder
(MDD).
Methods: At two sites, female outpatients (n = 353), aged 18–70, with recurrent MDD received 12–14 weeks of
cognitive therapy (CT). Menopausal status and age were based on self-report. In the parent study, nonresponse
to therapy was defined as persistence of a major depressive episode (MDE) as defined by the DSM-IV or a final
Hamilton Rating Scale for Depression-17-Item (HRSD17) score of ‡ 12 or both. More traditional definitions of
response (at least a 50% reduction in pretreatment HRSD17) and remission (a final HRSD17 £ 6) were also
examined.
Results: Controlling for pretreatment HRSD17 scores, there were no significant differences found in the rates of
response to CT or symptom status among premenopausal, perimenopausal, and postmenopausal women.
Conclusions: We found no support for the hypotheses that response to CT or the rates of change in depressive
symptoms are moderated by reproductive status. The findings, however, are limited by the absence of early
follicular phase serum sampling/analysis to estimate hormone levels and the reliance on self-report to establish
menopausal status. These data motivate a full investigation of the effects of reproductive status on response to
psychosocial interventions.
Introduction
Over 30 years ago, Weissman and Klerman
1 con-
cluded that women had an increased prevalence of de-
pression. Today, although no gender differences are found in
the overall rates of mental illness, the risk of experiencing an
episode of major depressive disorder (MDD) remains double
for women over that for men, according to contemporary
epidemiologic findings.2,3 Reasons proposed for this disparity
include epidemiologic measurement bias (i.e., sampling bias,
definition of case, differences in incidence, and assessment
bias), biologic sex differences, social norms, and psychologic
vulnerabilities.4
Recent longitudinal studies also suggest that the meno-
pausal transition, in particular, can be a period of increased
mood lability as well as significantly increased risk for new-
onset depression.5–8 Perimenopausal depression is diag-
nosed when an onset of MDD in midlife can be associated
with menstrual cycle irregularity or somatic symptoms of
the menopausal transition, a process of diagnosis that is
based on the overall clinical picture.9 The World Health
Organization (WHO) defines perimenopause as a period
characterized by hormonal variability, change in menses
pattern, often accompanied by somatic and mood symp-
toms, typically beginning between 2 and 8 years before
menopause and extending up to 1 year after the final men-
ses.10 Menopause is considered achieved after 12 months of
amenorrhea (not due to another cause). In the United States,
the median ages for this transition are 47.5 for perimeno-
pause and 51 for completed menopause, with the average
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time between regular cycles and amenorrhea lasting ap-
proximately 8 years.11
Fluctuating hormones as a moderator of treatment
Included within studies of perimenopausal depression are
investigations of the impact of hormonal milieu on treatment
response. Because differential gender responses to antide-
pressant medications are reported in the literature,12,13 several
investigators have also examined whether reproductive sta-
tus itself influences responsiveness to antidepressant medi-
cation, with most using age cutoffs as proxies for
postmenopausal identification (age thresholds varying from
45 to 56).12,14–17 Findings are mixed, with some study teams
reporting differential response rates to classes of antidepres-
sants between premenopausal and postmenopausal wom-
en.12,14,18,19 Specifically, Harvey et al.19 found in a clinical trial
comparing imipramine with sertraline that premenopausal
women experienced depressive symptom deterioration at a
greater proportion of their visits than did postmenopausal
women (8.6% vs. 4.5%, p < 0.01) or men (5.9%, p < 0.01). Con-
versely, another study team reported that younger women
and men ( < 50 years of age) and older men ( > 50 years of age)
had significantly higher remission rates (36%, 36%, and 35%,
respectively) during treatment than did older women (28%,
Wald chi-square = 4.2, df 1, p < 0.04).14 However, others have
failed to confirm such age-related differences in psychotropic
treatment response.15,17
In studies of psychotherapy, gender has not been a con-
sistent predictor of outcome, although most study designs are
limited by differential dropout rates, small sample sizes, or
small numbers of male participants.20,21 To our knowledge,
there have been no investigations of potential influences of
reproductive status on women’s response to psychotherapy.
Given the cited research suggesting differential rates of
symptomatic worsening and remission across reproductive
groups of women receiving pharmacotherapy,19 might peri-
menopausal processes moderate symptomatic response to
psychotherapy?
Study aims
In view of this question surrounding potential associations
between reproductive status and the response to psycho-
therapy for depression, data collected in a larger study (in
which gender did not predict response) ( Jarrett et al., un-
published observations) were analyzed for the purpose of
comparing (1) response to cognitive therapy (CT) for de-
pression in premenopausal, perimenopausal, and postmeno-
pausal women and (2) rate of change in depressive symptoms
over the course of 12–14 weeks of CT in the three groups of
women.
Consistent with the biologic theories (hormonal instabili-
ty/fluctuation and estrogen withdrawal) associating mood
lability and depressive symptoms with women’s reproduc-
tive events (i.e., puberty, pregnancy, postpartum, and the
perimenopause; Table 1), we hypothesize women who have
completed menopause (no longer menstruating) will experi-
ence greater benefit (response and faster relief from depres-
sive symptoms) from CT compared to premenopausal or
perimenopausal women. Further, consistent with epidemio-
logic findings and similar hypotheses in pharmacologic
studies,6,19,22 we hypothesized that the rate of change in de-
pressive symptoms for women who are perimenopausal
would be slower than that of premenopausal or postmeno-
pausal women.
Materials and Methods
The rationale and design of the Continuation Phase Cog-
nitive Therapy Relapse Prevention (C-CT-RP) trial and the
specific elements of the protocol and cognitive therapy have
been detailed elsewhere.25 The trial was registered at Clinical-
Trials.gov (NCT00118404, NCT00183664, and NCT00218764).
Data were collected at two sites: the Department of Psychiatry,
Psychosocial Research and Depression Clinic at The University
of Texas Southwestern Medical Center (Principal Investigator:
Robin B. Jarrett, Ph.D.) and in the Mood Disorders Treatment
Research Program at the Western Psychiatric Institute and
Clinic of the University of Pittsburgh Medical Center (Principal
Investigators: Michael E. Thase, M.D. and Edward Friedman,
M.D.). Research was approved by the Institutional Review
Boards at each site before initiation and was reviewed annually
through completion of the study. A summary of the procedures
affecting the sample analyzed follows (Fig. 1).
Participants
From January 2000 to July 2008, 523 outpatients (353 wo-
men, 67%) between the ages of 18 and 70 years, diagnosed
with recurrent MDD, were recruited from community settings
using institutionally approved materials. Written informed
consent was obtained at study screening and again at en-
rollment. Diagnosis of recurrent MDD was established ac-
cording to the criteria in the Diagnostic and Statistical Manual of
Mental Disorders, 4th ed. Text Revision (DSM-IV-TR).26 Only
data from women are included in this discussion.
Inclusion/exclusion criteria
Consenting outpatients were included when they (1) re-
mitted between depressive episodes, had at least one prior
episode with complete interepisode recovery, or had ante-
cedent dysthymic disorder, and (2) scored ‡ 14 on the Ha-
milton Rating Score for Depression, 17-item (HRSD17) at the
initial and second interviews. Individuals were excluded if
they (1) reported severe or poorly controlled concurrent
medical disorders that may cause depression or require
medication that could cause depressive symptoms, (2) suf-
fered comorbid DSM-IV illnesses, such as bipolar disorder,
active alcohol or substance dependence, primary obsessive
compulsive disorder, or eating disorders, (3) could not
Table 1. Lifetime Prevalence of Major Depressive
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complete English language questionnaires, (4) were active
suicide risks, (5) had previously not responded to a trial of at
least 8 weeks of CT conducted by a certified therapist, (6) had
previously not responded to at least 6 weeks of 40 mg of flu-
oxetine, (7) were pregnant or planned to become pregnant
during the first 11 months after intake, or (8) did not provide
informed consent. All excluded individuals were referred for
nonprotocol treatment (e.g., hospitalization, pharmacother-
apy, psychotherapy). If indicated after a review of medical
history, a physical examination and appropriate laboratory
tests were obtained to ensure that patients were diagnostically
eligible. Patients who were taking psychotropic medication
agreed to be withdrawn from the medication for at least 1
week before study entry.
Defining reproductive status
The investigator-developed demographic measure used
in the study prompted the patient to record the presence or
absence of hysterectomy, date of last menstrual period, and
reproductive status. Women who self-reported the comple-
tion of menopause were considered postmenopausal
(n = 59), and women who reported hysterectomy were de-
fined as surgically menopausal (n = 47).27 For the rest of the
sample, reproductive status was inferred by age or the
presence of a menstrual cycle in the previous year, with
women > 18 years of age but < 42 classified as premeno-
pausal (n = 169) and those between 42 and 51.5 considered
perimenopausal (n = 74).22 Two women older than 51.5 who
did not complete the menopausal item but did not endorse
menstruation in the previous year were designated as
postmenopausal (n = 2), and 2 women older than 51.5 years
but reporting menstruation in the last year were transferred
to the perimenopausal group. Thus, the sample included 169
premenopausal, 76 perimenopausal, and 108 postmeno-
pausal women. We believe this strategy provides a more
accurate classification than relying on age alone and is con-
sistent with strategies used by others.28
Procedures
The parent study contained four phases: (1) initial evalua-
tion, (2) 16–20 individual sessions of acute phase CT, (3) 8
months of continuation phase treatment or follow-up only,
and (4) 2 additional years of follow-up free of protocol treat-
ment. We report findings from only the first two phases, using
outcomes from the first blinded evaluation at the end of acute
phase CT.
Acute phase CT
Acute phase CT consisted of 16–20 individual psycho-
therapy sessions, occurring over a maximum of 14 weeks
and conducted according to the Beck treatment manual.29
Sessions 1–8 were held twice weekly. Patients who experi-
enced at least a 40% reduction in HRSD17 scores by session 8
(early responders) began weekly sessions; patients who did
not experience a 40% reduction (late responders) continued
biweekly sessions for 4 additional weeks. Sixteen experi-
enced therapists (11 male and 5 female) trained in CT con-
ducted the treatment, meeting nearly weekly for supervision
sessions at each site. Sessions were videotaped, randomly
selected, and rated for adherence and competence according
to the Cognitive Therapy Scale (CTS) by therapy supervisors
and their teams.30 No pharmacotherapy was provided dur-
ing acute phase CT.
Measures
Patient background. Each patient completed an investi-
gator-designed form to report demographics (e.g., age,
FIG. 1. The Consort 2010
flow diagram for division by
strata. CT, cognitive therapy.
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gender, ethnicity, marital status), use of medications, drugs,
and alcohol; medical history; and reproductive status.
Structured Clinical Interview for DSM-IV (SCID).31 The
SCID is a clinician-administered, semistructured interview
widely used in North American research to facilitate diag-
nosis of a range of psychiatric diagnoses according to the
DSM-IV.32 With the exception of dysthymic disorder, the re-
liability has been reported to be good to excellent (kappa
ranging from 0.60 to 0.86) in diagnostic categories contained
in the anxiety and mood disorder modules.33 The screening,
mood disorders, and mood differential modules were used to
establish or rule out a diagnosis of MDD in participants.
Hamilton Rating Scale for Depression (HRSD). The
HRSD17
34 is a clinician rating scale designed to assess the se-
verity of depressive symptoms in patients already diagnosed
with MDD; higher scores reflect greater symptom severity. The
clinician rates each of the 17 items on either a 3-point or 5-point
scale, and the total score is determined by summing the item
scores. Scores ‡ 24 indicate severe depression (typical of in-
patients), scores £ 17 suggest mild symptoms (more typical of
outpatients), and scores £ 6 indicate an absence of depressive
symptoms (i.e., remission). With highly trained raters, the
HRSD17 has been found to have an excellent interrater reli-
ability (r = 0.85).35 There are few data on the internal consis-
tency of the measure, but Schwab et al.36 found that individual
items correlated with a total score of 0.45–0.78. Regarding va-
lidity, Knesevich et al.37 found HRSD17 change scores to be
correlated 0.68 with global change scores, and numerous
studies have shown significant differences in the HRSD17
scores of normal controls and patients with depression, sup-
porting its criterion validity. The measure has also shown good
convergent validity with other clinical self-report depression
measures (r = approximately 0.83 and 0.70, respectively).35 The
current report makes use of 19 assessments, and the median
alpha internal consistency is 0.784 (range 0.504–0.852).
Blinded clinical evaluations
A clinical evaluator masked to patient risk and treatment
assignment collected symptom severity measures and as-
sessed diagnostic status of the patients. All videotaped blin-
ded evaluations were administered within approximately 7
days of their last acute treatment session, at the time the pa-
tient exited the protocol, or at any other time when a relapse or
recurrence was suspected.
Outcome definitions
In the parent study, patients were judged to have not re-
sponded to acute phase CT if they (1) still met DSM-IV criteria
for a major depressive episode (MDE) or (2) had a final
HRSD17 score of > 12, or (3) both. In this report, patients are
also classified as responders if they achieved at least a 50%
reduction in pretreatment HRSD17 scores at study exit and as
remitters if they had a final HRSD17 £ 6 at study exit.38
Statistical analyses
All analyses were generated using SAS software, version
9.2. The study statistician (A.M.) performed a power analysis
on the protocol response data for the logistic regression
model, with menopausal status as the independent variable
(regressor) of interest and using the HRSD17 score as a cov-
ariate. Based on this post-hoc power analysis and a sample size




Race/ethnicity, marital and employment status, and years
of education of the 353 female participants as reported at the
diagnostic evaluation are all reported in Table 2, as are illness
descriptors. The mean HRSD17 score at final pretreatment
evaluation was 20.7 (4.0), with no significant difference
among the three reproductive status groups, although there
were significant pretreatment demographic and clinical dif-
ferences among the groups. Demographically, Caucasian
women (78.5%, 277 of 353) and women engaged in full-time
employment (42.0%, 147 of 353) were overrepresented in the
sample (chi-square = 34.3, p < 0.0001 and chi-square = 48.7,
p < 0.0001, respectively). Of clinical relevance, perimenopau-
sal and postmenopausal women reported older age at onset of
depression (chi-square = 62.0F, p < 0.0001), longer duration of
the current episode (chi-square = 11.3, p < 0.004), and longer
duration of illness (chi-square = 101.5F, p < 0.0001).
Number of CT sessions attended
Seventy-seven of the 353 (21.81%) women did not complete
the acute phase CT (attending < 14 of 16 sessions if consid-
ered an early responder or < 18 of 20 sessions if a late re-
sponder). The noncompleters had an average of 5.78
(standard deviation [SD] = 5.32, median = 5) sessions of acute
phase therapy. Among the 276 completers, 130 (47.10%) were
early responders, with an average of 15.99 (SD = 0.44, medi-
an = 16) sessions of acute phase CT. One hundred forty-six of
the 276 (52.89%) acute phase CT completers were late re-
sponders and attended an average of 19.97 sessions (SD = 0.22,
median = 20; Table 3). The significant differences between
those women who completed the acute phase CT (78.19%, 276
of 353) and those who did not were the same as the demo-
graphic pretreatment differences, namely, Caucasian women
represented 65.44% (231 of 276) of the completers (chi-
square = 12.94, p < 0.0001), and women employed full-time
represented 35.14% (123 of 274) of the completers (chi-
square = 15.84, p < 0.0147).
Response to CT
Hypothesis 1. Do more postmenopausal women respond
to CT than do premenopausal or perimenopausal women?
Based on hormonal theories, we hypothesized that a higher
proportion of postmenopausal (natural or surgical) women
would respond or have reduced depressive symptoms after
CT compared to premenopausal and perimenopausal wo-
men. The results did not allow us to reject the null hypothesis
that the groups differed.
In the group of premenopausal women, 37.3% (63 of 169)
were classified as nonresponders, using the protocol defini-
tion, compared to 40.8% (31 of 76) in the perimenopausal
group and 37.0% (40 of 108) in the postmenopausal group.
Using logistic regression analysis, with the pretreatment
HRSD17 score included in the model as a covariate and
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reproductive status entered as an independent variable, there
were no statistically significant differences in nonresponse
rates (chi-square [df, 2] = 0.45, p £ 0.799; for perimenopausal
women, OR = 0.837, 95% confidence interval [CI] 0.48-1.47;
for postmenopausal women, OR = 1.01, 95% CI 0.60-1.68).
Regarding the conventional definition of remission
(HRSD17 £ 6 at study exit), 32.5% (55 of 169) of premeno-
pausal women in the study sample were classified as remit-
ted compared to 26.3% (20 of 76) of perimenopausal and
27.8% (30 of 108) of postmenopausal women. Adjusted for
Table 2. Pretreatment Demographic, Clinical, and Cognitive Characteristics












Demographic Race, n (%) Chi-square = 34.3e
p < 0.0001
White 277 (78.5) 111 (65.7) 65 (85.5) 101 (93.5)
Black 41 (11.6) 30 (17.8) 7 (9.2) 4 (3.7)
Hispanic 22 (6.2) 17 (10.1) 2 (2.6) 3 (2.8)
Other 13 (3.7) 11 (6.5) 2 (2.6) 0 (0.0)
Age mean (SD) 41.7 (12.4) 30.8 (6.1) 46.5 (2.9) 55.3 (6.8) F = 623.1d
p < 0.0001
Marital status, n (%) Chi-square = 4.4
p < 0.112
Single 197 (55.8) 103 (61.0) 42 (55.3) 52 (48.2)
Partnered 156 (44.2) 66 (39.0) 34 (44.7) 56 (51.8)
Education mean (SD) 14.9 (2.9) 14.8 (2.8) 15.4 (3.0) 14.7 (3.0) F = 1.4
p < 0.247
Employment, n (%)
Full-time 147 (42.0) 76 (45.2) 31 (41.9) 40 (37.0) Chi-square = 48.7
Part-time 49 (14.0) 22 (13.1) 8 (10.8) 19 (17.6) p < 0.0001
Homemaker/caregiver 30 (8.6) 11 (6.6) 8 (10.8) 11 (10.2)
Student 17 (4.9) 16 (9.5) 1 (1.4) 0 (0.0)
Retired 11 (3.1) 0 (0.0) 0 (0.0) 11 (10.2)
Other 16 (4.6) 4 (2.4) 6 (6.1) 6 (5.6)
Unemployed 80 (22.9) 39 (23.2) 20 (27.0) 21 (19.4)
Severity and
Clinical
HRSD17 At final pretreatment
follow-up
20.7 (4.0) 20.8 (4.1) 20.5 (3.7) 20.7 (4.2) F = 0.1
p < 0.931
Age at onset, mean (SD), years 20.8 (10.3) 16.1 (6.2) 24.4 (10.3) 25.5 (12.1) Chi-square = 62.0f
Median 18.0 16.0 24.0 23.0 p < 0.0001
Length of current episode,
mean (SD), months
22.9 (36.2) 16.1 (22.0) 30.6 (54.8) 28.2 (36.2) Chi-square = 11.3f
Median 9.0 7.0 10.0 14.0 p < 0.004
Length of illness, mean (SD)
years
20.4 (11.7) 14.2 (7.4) 21.6 (10.2) 29.3 (12.1) Chi-square = 101.5f
Median 19.0 14.0 22.0 29.5 p < 0.0001




Current 167 (47.3) 85 (50.3) 37 (48.7) 45 (41.7) Chi-square = 2.0
p < 0.360
Lifetime 270 (76.5) 138 (81.7) 55 (72.4) 77 (71.3) Chi-square = 4.8
p < 0.089
Current double depression, n (%) 19 (5.4) 6 (3.6) 4 (5.3) 9 (8.3) Chi-square = 3.0
p < 0.227
Depressive subtype, n (%)
RDC endogenous, definite 133 (38.3) 62 (37.6) 36 (48.0) 35 (32.7) Chi-square = 5.4
p < 0.109
DSM-IV melancholia 130 (37.0) 70 (41.4) 30 (40.0) 30 (28.0) Chi-square = 5.4
p < 0.068
an reduced 165 RDC endogenous definite.
bn reduced to 75 for DSM-IV melancholia and RDC endogenous definite.
cn reduced to 107 for DSM-IV melancholia and RDC endogenous definite.
dF statistics are from one-way ANOVA analysis.
eChi-square statistics for contingency tables.
fChi-square statistics are from Kruskal-Wallis test for medians.
HRSD17, 17-item Hamilton Rating Scale for Depression; SD, standard deviation; RDC, research diagnostic criteria.
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pretreatment HRSD17, there was no statistically significant
difference in the remission rate among the three groups (chi-
square [df, 2] = 0.92, p = 0.630; for perimenopausal women,
OR = 1.366, 95% CI 0.51-3.70; for postmenopausal women,
OR = 1.879, 95% CI 0.51-6.92).
Similarly, 52.1% (88 of 169) of premenopausal women ex-
perienced at least 50% reduction in the pretreatment HRSD17
compared to 50.0% (38 of 76) in the perimenopausal group,
and 50.9% (55 of 108) in the postmenopausal group. Adjusted
for pretreatment HRSD17, there were no statistically signifi-
cant differences between women reporting at least 50% re-
duction in pretreatment HRSD17 (chi-square [df, 2] = 0.14,
p = 0.931; for perimenopausal women, OR = 0.860, 95% CI
0.39-1.89; for postmenopausal women, OR = 0.864, 95% CI
0.31-2.38).
Hypothesis 2. Do premenopausal and perimenopausal
women have a lower rate of change in depressive symptoms
(as measured by the HRSD17 at each acute phase visit) than
postmenopausal women during their participation in acute
phase CT? In view of the mood lability and increased de-
pressive symptoms associated with the menstrual cycle as
well as the menopausal transition,39,40 we hypothesized that
the slope of HRSD17 scores for women who have completed
menopause would be steeper than that of women reporting
menstrual cycles.
Although the HRSD17 scores decreased dramatically dur-
ing the course of acute phase therapy (F1,640 = 576.07,
p < 0.001), the slopes of HRSD17 scores from the two groups
did not differ significantly. Using a hierarchical linear model
with all available HRSD17 scores across CT as the dependent
variable and reproductive status (age categories) and pre-
treatment HRSD17 score as covariates, we estimated random
intercepts as well as random slopes, measuring the rate of
change over time within each woman, considering time a
random effect. The HRSD17 scores from the premenopausal;
perimenopausal, and postmenopausal women were com-
pared in terms of mean intercept (mean HRSD17 at the be-
ginning of the acute phase) and slope (rate of change over the
course of acute phase). There were no statistically significant
differences among premenopausal, perimenopausal, and
postmenopausal women in terms of mean HRSD17 levels at
the beginning of the acute phase treatment (F2,511 = 0.05,
p = 0.951). Additionally, there were no statistically significant
differences found among premenopausal, perimenopausal,
and postmenopausal women in terms of rate of decrease in
HRSD17 score during the acute phase therapy (F2,638 = 2.23,
p = 0.108).
Discussion
Although depressive symptoms have long been linked
with hormonal status in women, there was no evidence that
reproductive status influenced outcomes in this large sample
of women receiving CT for recurrent MDD. Of menstruating
women (233 of 353) in the sample, 75% (176) reported expe-
riencing cycle-related changes in mood lability (50.2%, 117 of
176, premenopausal; 25.3%, 59 of 176, perimenopausal; 0%
postmenopausal). Of the 24.5% (57 of 233) who reported no
cycle-related mood lability, 73.68% (42 of 57) were premeno-
pausal, and 26.32% (15 of 57) were perimenopausal (0%
postmenopausal). Given our inability to reject the null hy-
pothesis in a population of women who dominantly report
cycle-related mood changes, the findings provocatively sug-
gest CT may have moderated the presumed association be-
tween depressive symptoms and women’s hormonal
fluctuations. Recent biologic work suggests that independent
of pharmacologic interventions, psychotherapy may stimu-
late changes in cAMP response element-binding protein
(CREB) phosphorylation and brain-derived neurotrophic
factor (BDNF) plasma levels in the brain, both implicated in
the biomarkers of depression and anxiety.41 Other bodies of
research posit cognitive behavioral therapy (CBT) may nor-
malize amygdala and dorsolateral prefrontal cortical activity
in individuals with depression; this is supported by functional
imaging demonstrating brain changes.42, 43
This is the first investigation of potential relationships be-
tween psychotherapy response and female reproductive sta-
tus; however, there is a small body of literature reporting on
potential relationships between antidepressant therapy and
hormonal status. Consistent with our findings, Cassano
et al.15 did not find a differential symptomatic response to
fluoxetine treatment in a sample of premenopausal, perime-
nopausal, and postmenopausal women diagnosed with
MDD. In a study of men and women diagnosed with chronic
MDD or MDD superimposed on dysthymia (double depres-
sion), however, premenopausal women deteriorated at a
greater proportion of their visits than did postmenopausal
women or men, leading the investigators to conclude that acute
worsening of depression was associated with reproductive
variables.19 Other research teams have also reported interac-
tions between age and selective serotonin reuptake inhibitor
Table 3. Average Number of Acute Phase Sessions by Menopause Status
for Completers and Noncompleters of Acute Phase Cognitive Therapy
Group of women Total Premenopausala Perimenopausalb Postmenopausalc
Noncompleters, n = 77* 5.8 (5.3) 3.9 (4.4) 7.7 (6.2) 8.3 (4.8)
Completers
Early Responders, n 130 16.0 (0.4) 15.9 (0.3) 16.2 (0.8) 16.0 (0.2)
Late Responders, n = 130 20.0 (0.2) 20.0 (0.1) 19.9 (0.2) 20.0 (0.3)
aAmong the premenopausal women, 41 are noncompleters, 67 are early responders, and 61 are late responders.
bAmong the perimenopausal women, 19 are noncompleters, 23 are early responders, and 34 are late responders.
cAmong the postmenopausal women, 17 are noncompleters, 40 are early responders, and 51 are late responders.
*p £ 0.05 comparing patients in the three groups;
p £ 0.05 comparing patients in the premenopausal and perimenopausal groups;
p £ 0.05 comparing patients in the premenopausal and postmenopausal groups;
p £ 0.05 comparing patients in the perimenopausal and postmenopausal groups.
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(SSRI) response, with postmenopausal women demonstrating
poorer response to medication.14 Reproductive status has also
been associated with differential responses to sertraline and
imipramine, with women more likely to respond to sertraline
and men more likely to respond to imipramine (Wald chi-
square = 6.80, df = 1, p = 0.009).12
It is important to note that no gender differences in re-
sponse to CT were found in the complete dataset including
men (chi-square = 0.04, p = 0.85; Jarrett et al., unpublished
observations). Indeed, a recent review reported that the evi-
dence available fails to support differential response rates of
men and women with unipolar depression to psychothera-
py.21 In the related field of pharmacologic response, studies
investigating associations between gender and antidepressant
medication responses are equivocal, with some groups dem-
onstrating differential responses,12,44 and others failing to find
such distinctions.16,45,46 However, authors consistently con-
clude that insufficient research has been conducted to fully
address the questions surrounding potential hormonal me-
diators or moderators of treatment response.
Limitations
Inferring hormonal status solely by self-report or chrono-
logic age limits confident interpretation of these results. Simply
using age for hypothesizing perimenopausal status introduces
age-related confounders that may mediate or moderate out-
comes alongside reproductive status. In addition, information
gathered about hormonal interventions was not complete,
preventing identification of women currently on any form of
hormonal therapy (item inquired about hormonal contracep-
tion only). It is notable, however, that none of the women we
categorized as postmenopausal reported cycle-related changes,
indicating that assignment was likely accurate. As investiga-
tors did not collect information about hormone replacement
therapy (HRT), study findings may be confounded by un-
known moderators or mediators related to such hormone
augmentation. Further limitations to our conclusions include
lack of a control group and selection of patients with recurrent
depression or dysthymic disorder for study. Characteristics of
this subset of depressed women may impact on treatment re-
sponse in a manner not representative of the treatment re-
sponse by women experiencing a first onset of depression.
Implications for future research
As far as we have found in the literature, this is the largest
study of adult females receiving psychotherapy for recurrent
MDD, a population strongly represented in primary care
patient visits.47 Future research could inform this inquiry
further and add confidence by including biologic measures of
follicular phase status, more extensive reproductive-related
demographic descriptors (such as average length of men-
strual cycle, number of cycles in the previous 12 months,
previous or ongoing use of HRT), and inquiry surrounding
known age-related confounders (e.g., caring for aged parents,
quality of life, status/independence of children, employment
status).
Conclusions
Despite decades of research suggesting depressive symp-
toms are linked to menopause as well as the general public
belief that women are more symptomatic around menstrua-
tion, we found no parallel differences in depressive symptom
response or rate of symptom change among menstruating,
perimenopausal, or postmenopausal women during acute CT
for recurrent depression. Future research advantaged by early
follicular phase serum sampling/analysis to establish hor-
mone levels could further inform hypotheses about the link
between depressive symptoms and hormonal status as well as
the potential benefits of CT to moderate such an association.
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